相关实验视频
Updated: Jun 25, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
通道阻塞剂和帕金森病:系统性审查和元分析
Junyu Lin1, Dejiang Pang1, Chunyu Li1
1Laboratory of Neurodegenerative Disorders, Department of Neurology, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Therapeutic advances in neurological disorders
|May 21, 2024
概括
通道阻断剂 (CCB) 可能降低患帕金森病 (PD) 的风险. 这一元分析表明一种保护性关联,尽管需要对疾病修饰进行进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 通道是帕金森病 (PD) 中神经保护的潜在治疗标.
- 之前关于通道阻断剂 (CCB) 和PD风险的研究已经产生了不一致的结果.
研究的目的:
- 系统地审查和元分析CCB使用与患PD风险之间的关联.
- 评估CCB使用对PD进展的影响.
主要方法:
- 在PubMed,Embase和Cochrane图书馆进行了全面的文献搜索,寻找2023年5月之前发表的研究.
- 包括专注于帕金森病和通道阻断剂的研究.
- 数据分析包括对9项关于PD风险的研究的元分析和对5项关于PD进展的研究的系统审查,其中包括2,961,695名参与者.
主要成果:
- 分析表明,CCB使用与PD风险降低有关 (相对风险:0.78,95% CI:0.62-0.99).
- 观察到显著的异质性,需要使用随机效应模型进行分析.
结论:
- CCB的使用表明与帕金森病风险降低有显著的关联.
- 需要进一步调查,以确定CCB是否在PD中具有疾病修饰作用.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
497
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
497
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
490
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
490
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Antiepileptic Drugs: Calcium Channel Blockers
373
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
373

